Pharmerging

Global Market Trajectory & Analytics

MCP16682

EXECUTIVE ENGAGEMENTS

* Login for a full stack data experience

DATE

APR 2021

TABLES

36

88

EDITION

9

PRICE

USD 4950

CODE

MCP16682

*Engagement stats are ongoing and dynamic

COMPETITIVE METRICS

	COMPANY	D S N T % *
	Abbott Laboratories, Inc.
	AbbVie, Inc.
	Alexion Pharmaceuticals, Inc.
	Allergan PLC
	Amgen, Inc.
	Aspen Pharmacare Holdings Ltd.
	Astellas Pharma, Inc.
	AstraZeneca PLC
	Baxter International, Inc.
	Bayer AG

SUBMIT

Note: Best viewed in Landscape Mode

RESEARCH MODULES MARKET TRENDS EXECUTIVES

HIGHLIGHTS & REPORT INDEX

Amid the COVID-19 crisis, the global market for Pharmerging estimated at US$817.6 Million in the year 2020, is projected to reach a revised size of US$1.6 Billion by 2027, growing at aCAGR of 9.9% over the period 2020-2027. Pharmaceutical, one of the segments analyzed in the report, is projected to record 8.4% CAGR and reach US$960.5 Million by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Healthcare segment is readjusted to a revised 12.5% CAGR for the next 7-year period.

The Pharmerging market in the U.S. is estimated at US$242.2 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$274.5 Million by the year 2027 trailing a CAGR of 9.3% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 8.9% and 8.2% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 8.2% CAGR.

SELECT PLAYERS

Abbott Laboratories; AbbVie, Inc.; Alexion Pharmaceuticals, Inc.; Allergan PLC; Amgen, Inc.; Aspen Pharmacare Holdings Ltd.; Astellas Pharma, Inc.; AstraZeneca PLC; Baxter International, Inc.; Bayer AG; Biogen, Inc.; Boehringer Ingelheim International GmbH; Bristol-Myers Squibb Company; Celgene Corporation; CSL Behring; Daiichi Sankyo Co., Ltd.; Eisai Co., Ltd.; Eli Lilly and Company; Endo International PLC; F. Hoffmann-La Roche AG; GlaxoSmithKline PLC; Grifols SA; H. Lundbeck A/S; Hospira, Inc.; Johnson & Johnson; Kyowa Hakko Kirin Co., Ltd.; Mallinckrodt Pharmaceuticals; Mitsubishi Tanabe Pharma Corporation; Mylan Pharmaceutical Pvt. Ltd.; Novartis AG; Novo Nordisk A/S; Otsuka Pharmaceutical Co., Ltd.; Pfizer, Inc.; Sanofi SA; Shire PLC; Stada Arzneimittel AG; Sun Pharmaceutical Industries Ltd.; Takeda Pharmaceutical Co., Ltd.; Teva Pharmaceutical Industries Ltd.; UCB SA

SEGMENTS

» Product (Pharmaceutical, Healthcare)

GEOGRAPHIES

» World » United States » Canada » Japan » China » Europe » France » Germany » Italy » United Kingdom » and Rest of Europe » Asia-Pacific » Rest of World

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

Influencer Market Insights

World Market Trajectories

Pharmerging Market to Grow Steadily, Driven by Rapid Growth of the Pharma Sector

Table: Worldwide Pharmaceutical Market Growth Projections by Regional Group: 2018 and 2022

Table: Breakdown of Growth Percentage and Spending in Billion USD for Pharmerging Markets by Country: 2007-2022

Pharmaceutical Segment to Register Strong Growth

Table: Total Spending on Medicines (in Billion USD) in Select Emerging Pharmaceutical Markets: 2023

Table: Healthcare Market in Tier I Pharmerging Region (USD Billion) by Product: 2014-2025

Asia-Pacific Region to Retain Top Slot

Impact of Covid-19 and a Looming Global Recession

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

Growing Geriatric Population to Bode Well for Market Growth

Table: Total Breakdown of People Aged Over 60 by Development Groups: 1980 to 2050

Increase in Patient Numbers to Support Market Growth

Table: Top Therapeutic Areas by Spending (Billion USD) in Pharmerging Markets: 2018

Table: Select Therapy Areas Spending (Billion USD) in Pharmerging Markets: 2020

Increasing Preference for Generics to Spur Market Expansion

4. GLOBAL MARKET PERSPECTIVE

World Current & Future Analysis for Pharmerging by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR

World 7-Year Perspective for Pharmerging by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2020 & 2027

World Current & Future Analysis for Pharmaceutical by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR

World 7-Year Perspective for Pharmaceutical by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027

World Current & Future Analysis for Healthcare by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR

World 7-Year Perspective for Healthcare by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027

III. MARKET ANALYSIS

UNITED STATES

USA Current & Future Analysis for Pharmerging by Product - Pharmaceutical and Healthcare - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR

USA 7-Year Perspective for Pharmerging by Product - Percentage Breakdown of Value Sales for Pharmaceutical and Healthcare for the Years 2020 & 2027

CANADA

Canada Current & Future Analysis for Pharmerging by Product - Pharmaceutical and Healthcare - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR

Canada 7-Year Perspective for Pharmerging by Product - Percentage Breakdown of Value Sales for Pharmaceutical and Healthcare for the Years 2020 & 2027

JAPAN

Japan Current & Future Analysis for Pharmerging by Product - Pharmaceutical and Healthcare - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR

Japan 7-Year Perspective for Pharmerging by Product - Percentage Breakdown of Value Sales for Pharmaceutical and Healthcare for the Years 2020 & 2027

CHINA

China Current & Future Analysis for Pharmerging by Product - Pharmaceutical and Healthcare - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR

China 7-Year Perspective for Pharmerging by Product - Percentage Breakdown of Value Sales for Pharmaceutical and Healthcare for the Years 2020 & 2027

EUROPE

Europe Current & Future Analysis for Pharmerging by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR

Europe 7-Year Perspective for Pharmerging by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2020 & 2027

Europe Current & Future Analysis for Pharmerging by Product - Pharmaceutical and Healthcare - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR

Europe 7-Year Perspective for Pharmerging by Product - Percentage Breakdown of Value Sales for Pharmaceutical and Healthcare for the Years 2020 & 2027

FRANCE

France Current & Future Analysis for Pharmerging by Product - Pharmaceutical and Healthcare - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR

France 7-Year Perspective for Pharmerging by Product - Percentage Breakdown of Value Sales for Pharmaceutical and Healthcare for the Years 2020 & 2027

GERMANY

Germany Current & Future Analysis for Pharmerging by Product - Pharmaceutical and Healthcare - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR

Germany 7-Year Perspective for Pharmerging by Product - Percentage Breakdown of Value Sales for Pharmaceutical and Healthcare for the Years 2020 & 2027

ITALY

Italy Current & Future Analysis for Pharmerging by Product - Pharmaceutical and Healthcare - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR

Italy 7-Year Perspective for Pharmerging by Product - Percentage Breakdown of Value Sales for Pharmaceutical and Healthcare for the Years 2020 & 2027

UNITED KINGDOM

UK Current & Future Analysis for Pharmerging by Product - Pharmaceutical and Healthcare - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR

UK 7-Year Perspective for Pharmerging by Product - Percentage Breakdown of Value Sales for Pharmaceutical and Healthcare for the Years 2020 & 2027

REST OF EUROPE

Rest of Europe Current & Future Analysis for Pharmerging by Product - Pharmaceutical and Healthcare - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR

Rest of Europe 7-Year Perspective for Pharmerging by Product - Percentage Breakdown of Value Sales for Pharmaceutical and Healthcare for the Years 2020 & 2027

ASIA-PACIFIC

Asia-Pacific Current & Future Analysis for Pharmerging by Product - Pharmaceutical and Healthcare - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR

Asia-Pacific 7-Year Perspective for Pharmerging by Product - Percentage Breakdown of Value Sales for Pharmaceutical and Healthcare for the Years 2020 & 2027

REST OF WORLD

Rest of World Current & Future Analysis for Pharmerging by Product - Pharmaceutical and Healthcare - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR

Rest of World 7-Year Perspective for Pharmerging by Product - Percentage Breakdown of Value Sales for Pharmaceutical and Healthcare for the Years 2020 & 2027

IV. COMPETITION

Total Companies Profiled: 22

PREVIEW REPORT

YOUR PRIVACY MATTERS!

Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.

What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com

DIFFERENTIATORS

Integrity Trust Transparency

Our research offerings primarily draw upon unique perspectives of participating executives and their experiences in operating and strategy roles. These geo-focused insights enrich our projects .

What we are NOT - Our reports are not editorial exercises of remote analysts’ secondary source fed content that predominantly flood today’s off-the-shelf market report business. (A review of 262 publishers).

WHAT SETS US APART

FULL STACK DATA ACCESS

Primary Research Cluster Data
Influencer Engagement Stats
Evidence of Primary Research
List of Companies Engaged
Hundreds of Pages of Research
Peer Collaborative Interactions
Enterprise Data Exchanges
MarketGlassTM Platform Insider
Geographic Pricing Dynamics
Competitive Shares by Country
Brand Curation & Insights
Domain Expert Pool

Program Transparency: Clients have access to engagement stats of companies and executives. Clients may commission third-party audits of our influencer engagements at their expense.

Primary Research: We have a very successful incentive driven primary research program presenting a rich experience to participating executives. Featured company executives can sign up for a complimentary.

Collaborative Intelligence: Our platform presents a unique features for executives to collaborate with peers across geographies and participate on various product or regional perspectives for a collective unified insider project experience.

Global Brand Intelligence: We present competitive brand intelligence at the company level for players worldwide. Executives from brand owner companies participate to curate each brand for relevance and market presence.

Bespoke Updates: Our peer-to-peer online interactive platform enables client companies to build upon our project data stacks to build bespoke editions for internal sharing and use. Client company can build one complimentary update per year and unlimited updates for additional fee. Bespoke updates are fulfilled within a two-day turnaround.

Enterprise EcoConnect: Discretely bounce off queries to participant pool of executives. We can reach out to our participant pool based on specifics of geographic or domain acumen.

Renowned Support: We pride in our commitment to provide support to our clients. We go beyond the scope of the study to get you timely answers.

Complimentary Updates: Unlike the industry’s published PDF’s that are frozen in time from date of release, our research programs are ongoing and dynamic. Our reports are updated whenever there’s a major event impacting the marketplace. Your license offers seamless updates for one year.

No Fluff: We offer our clients the best CX with clean easy to read content. No verbose fluff. We offer clients full access to the entire stack of hundreds of pages of secondary research feeds used in our project via our online MarketGlass portal.

Pharmerging

Global Market Trajectory & Analytics

MCP16682

EXECUTIVE ENGAGEMENTS

POOL

INTERACTIONS

PARTICIPANTS

VALIDATIONS

COMPANIES

* Login for a full stack data experience

DATE

APR 2021

TABLES

36

PAGES

88

EDITION

9

PRICE

USD 4950

CODE

MCP16682

COMPETITIVE METRICS

COMPANY

% *

Abbott Laboratories, Inc.

AbbVie, Inc.

Alexion Pharmaceuticals, Inc.

Allergan PLC

Amgen, Inc.

Aspen Pharmacare Holdings Ltd.

Astellas Pharma, Inc.

AstraZeneca PLC

Baxter International, Inc.

Bayer AG

OUR EXPERT PANELS

Panelists are carefully chosen based on their domain expertise and market influence.

INFLUENCER INVITEE

WHY PARTICIPATE?

Expertise to the Power of YOU!

GLOBAL EXPERT PANEL

HIGHLIGHTS & REPORT INDEX

SELECT PLAYERS

SEGMENTS

GEOGRAPHIES

TABLE OF CONTENTS

PREVIEW REPORT

DIFFERENTIATORS

WHAT SETS US APART

FULL STACK DATA ACCESS